Company intelligence / Profile preview

BIAL

Trofa, Porto, Portugalbial.com ↗

Ownership: Private
Employees: ~935
Development stage: Commercial

Overview

BIAL has successfully developed and commercialized two drugs, Zebinix and Ongentys, which represent 55% of their turnover. Their lead asset BIA 28-6156 (formerly LTI-291) has completed Phase 1 trials and is currently in Phase 2 clinical trials for GBA1 Parkinson's disease. The ACTIVATE Phase 2 study had its first patient complete the full dose regimen in January 2025[10].

Therapeutic areas: Rare DiseasesCardiovascularNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

14 assets

eslicarbazepine acetate

Approved

13 more assets in the full pipeline.

Request access →

Partnerships

Sumitomo Pharma (10-year licensing agreement for Parkinson's medicine in Europe)

Beyond the preview

Go deeper on BIAL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIAL.

Explore the full profile